Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHOC | P08134 | 10/20 | 0.70 |
| ▸ | RHOA | P61586 | 10/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.52 |
| ▸ | TACR1 | P25103 | 1/20 | 0.50 |
| ▸ | CCR2 | P41597 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | CLPP | Q16740 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.47 |
| ▸ | MLYCD | O95822 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23014202 | 0.90 | ALDH1A1 (0.56) | RHOCRHOAALDH1A1CCR2GAA | |
| SCHEMBL23014506 | 0.88 | CCR2 (0.63) | RHOCRHOAALDH1A1DDR1CCR2 | |
| SCHEMBL23014290 | 0.85 | TACR1 (0.63) | RHOCRHOAALDH1A1TACR1 | |
| SCHEMBL12803414 | 0.82 | RHOC (1.00) | RHOCRHOAGAACLPP | |
| SCHEMBL23014293 | 0.82 | MEN1 (0.52) | ALDH1A1MEN1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL15707427 | 0.81 | RHOC (0.48) | RHOCRHOAALDH1A1TACR1CCR2 | |
| SCHEMBL6200322 | 0.81 | MEN1 (0.62) | ALDH1A1GAAMEN1CYP1A2CYP2D6 | |
| SCHEMBL23014346 | 0.78 | MEN1 (0.49) | ALDH1A1MEN1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL23014086 | 0.78 | ALDH1A1 (0.50) | ALDH1A1GAAMEN1PLA2G1BCYP1A2 | |
| SCHEMBL23014277 | 0.77 | SLC6A9 (0.58) | ALDH1A1MEN1CYP1A2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150924-A1 | NOVEL COMPOUND HAVING CANCER METASTASIS INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR INHIBITING CANCER METASTASIS AND INVASION OR TREATING COLORECTAL CANCER, COMPRISING COMPOUND | CELLGENTEK CO., LTD. (KR) | 2023-05-18 | — | — | US | claimed |
| EP-4019495-A1 | NOVEL COMPOUND HAVING CANCER METASTASIS INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR INHIBITING CANCER METASTASIS AND INVASION OR TREATING COLORECTAL CANCER, COMPRISING COMPOUND | Cellgentek Co., Ltd (KR) | 2022-06-29 | — | — | EP | claimed |
| WO-2021034087-A1 | NOVEL COMPOUND HAVING CANCER METASTASIS INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR INHIBITING CANCER METASTASIS AND INVASION OR TREATING COLORECTAL CANCER, COMPRISING COMPOUND | 주식회사 셀젠텍 | 2021-02-25 | — | — | WO | claimed |
| US-20230150924-A1 | NOVEL COMPOUND HAVING CANCER METASTASIS INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR INHIBITING CANCER METASTASIS AND INVASION OR TREATING COLORECTAL CANCER, COMPRISING COMPOUND | CELLGENTEK CO., LTD. (KR) | 2023-05-18 | — | — | US | disclosed |
| US-20230150924-A1 | NOVEL COMPOUND HAVING CANCER METASTASIS INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR INHIBITING CANCER METASTASIS AND INVASION OR TREATING COLORECTAL CANCER, COMPRISING COMPOUND | CELLGENTEK CO., LTD. (KR) | 2023-05-18 | — | — | US | disclosed |
| EP-4019495-A1 | NOVEL COMPOUND HAVING CANCER METASTASIS INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR INHIBITING CANCER METASTASIS AND INVASION OR TREATING COLORECTAL CANCER, COMPRISING COMPOUND | Cellgentek Co., Ltd (KR) | 2022-06-29 | — | — | EP | disclosed |
| EP-4019495-A1 | NOVEL COMPOUND HAVING CANCER METASTASIS INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR INHIBITING CANCER METASTASIS AND INVASION OR TREATING COLORECTAL CANCER, COMPRISING COMPOUND | Cellgentek Co., Ltd (KR) | 2022-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150924-A1 | NOVEL COMPOUND HAVING CANCER METASTASIS INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR INHIBITING CANCER METASTASIS AND INVASION OR TREATING COLORECTAL CANCER, COMPRISING COMPOUND | KNTC1, MED1, LEF1 | RHOC 2191/4885RHOA 1328/4885ALDH1A1 1404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.